Clinical

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency and generate cost savings for oncology practices without affecting efficacy or safety.

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK inhibitor–refractory disease.

Flu vaccination in older adults may prevent hospitalizations and cardiovascular events, saving lives and reducing health care costs, according to Marco del Riccio, MD.

The trial is investigating zanidatamab with/without tislelizumab plus chemotherapy in HER2-positive advanced or metastatic gastroesophageal adenocarcinoma.

A meta-analysis found β-blockers did not improve clinical outcomes in patients with acute MI and preserved LVEF, raising questions about routine use.

Explore the latest findings from the KATHERINE, PATINA, and HER2CLIMB-05 trials, highlighting advancements and challenges in breast cancer treatment.

Managed care organization and providers should conduct early formulary reviews and education to ensure rapid access to dextromethorphan-bupropion upon approval, potentially delaying facility placement for patients with Alzheimer disease.

Managed care organizations should evolve cost models to capture savings from dextromethorphan-bupropion’s safety profile, which avoids costly complications associated with traditional Alzheimer disease agitation therapies.

Recent trials highlight T-DXd's superior efficacy and manageable toxicity in treating high-risk HER2-positive breast cancer, reshaping treatment strategies.

Smart pill bottles may boost adherence to oral breast cancer therapies through daily reminders and tracking, though cost and technology barriers remain, says Steven Manobianco, MD.

The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy.

These results were presented during the press briefing ahead of the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Nimbus Therapeutics and Eli Lilly announce their partnership to develop a novel oral drug for patients with obesity and other metabolic disorders.

Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient outcomes and possible cures.

Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.

Population demographics and prevention efforts are key drivers of influenza burden, according to Marco del Riccio, MD.

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Panelists discuss how integrating xanomeline/trospium into clinical practice may expand safe and effective treatment options.

Shared decision-making—balancing clinical data with the patient's personal, logistical, and risk-tolerance factors—is essential for managing a chronic condition like follicular lymphoma.

Panelists discuss how the muscarinic pathway of xanomeline/trospium offers a safer, nondopaminergic approach to schizophrenia care.

Amrita Basu, PhD, says AI can transform health care by streamlining data, enhancing decision-making, and unlocking insights to improve patient outcomes.

Eric H. Yang, MD, emphasizes the need for collaboration and interventions to protect patients’ hearts during breast cancer treatment.

Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.